Chronic Kidney Disease Trial, Recruiting (NCT07232537)

Chronic Kidney Disease Trial, Recruiting NCT07232537 Sponsor: Bayer Condition: Chronic Kidney Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07232537 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Kidney Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults of any gender aged 18 or older
People who have been diagnosed by a doctor with chronic kidney disease (CKD) that is linked to type 2 diabetes
People for whom a doctor has decided to prescribe finerenone (10 mg or 20 mg) in line with how it is approved for use in their country, with treatment started no more than 8 weeks before or after signing the study consent form
The decision to start finerenone must have been made by the treating doctor before the study consent form is signed

Who may not be able to join:

People who are taking part in another clinical research trial at any point during this study
People for whom finerenone is not suitable according to the warnings and restrictions listed in the official prescribing information in their country (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+)1-888-84 22937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07232537

Sponsor: Bayer

Phase: Not Applicable

Status: Recruiting

Condition: Chronic Kidney Disease

Trial contact: (+)1-888-84 22937

More information: https://clinicaltrials.gov/study/NCT07232537

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults of any gender aged 18 or older
People who have been diagnosed by a doctor with chronic kidney disease (CKD) that is linked to type 2 diabetes
People for whom a doctor has decided to prescribe finerenone (10 mg or 20 mg) in line with how it is approved for use in their country, with treatment started no more than 8 weeks before or after signing the study consent form
The decision to start finerenone must have been made by the treating doctor before the study consent form is signed

Who may not be able to join:

People who are taking part in another clinical research trial at any point during this study
People for whom finerenone is not suitable according to the warnings and restrictions listed in the official prescribing information in their country (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Bayer

Registry

ClinicalTrials.gov

Start date

20 November 2025

Est. completion

30 September 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes (T2D); Descriptive summary of reasons for introducing finerenone; Descriptive summary of reasons for discontinuation of finerenone; Planned and actual duration of treatment with finerenone; Planned and actual dosing of finerenone; Descriptive summary of secondary therapies used in participants with CKD and T2D

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov